Oncobiologics (NYSE: ONS) and Burcon NutraScience Corp (NASDAQ:BUR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.
Insider & Institutional Ownership
1.4% of Burcon NutraScience Corp shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Oncobiologics and Burcon NutraScience Corp’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Oncobiologics||$1.40 million||29.08||-$41.02 million||N/A||N/A|
|Burcon NutraScience Corp||$62,800.00||435.49||-$4.42 million||($0.12)||-6.03|
Burcon NutraScience Corp has higher revenue, but lower earnings than Oncobiologics.
This is a breakdown of recent ratings for Oncobiologics and Burcon NutraScience Corp, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Burcon NutraScience Corp||0||0||0||0||N/A|
Oncobiologics presently has a consensus price target of $9.00, suggesting a potential upside of 445.45%. Given Oncobiologics’ higher possible upside, research analysts plainly believe Oncobiologics is more favorable than Burcon NutraScience Corp.
This table compares Oncobiologics and Burcon NutraScience Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Burcon NutraScience Corp||-2,884.35%||-162.68%||-92.88%|
Oncobiologics beats Burcon NutraScience Corp on 5 of the 9 factors compared between the two stocks.
Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company’s other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).
About Burcon NutraScience Corp
Burcon NutraScience Corp (Burcon) is a Canada-based company, which is engaged in development of functional and renewable plant proteins. The Company has developed a portfolio of composition, application and process patents originating from a core protein extraction and purification technology. The Company and its subsidiary have developed CLARISOY, a soy protein; and are developing Peazazz, a pea protein, and Puratein, Supertein and Nutratein, approximately three canola protein isolates. The Company’s products are targeted at the protein ingredient market and are particularly suited to health and wellness applications. The CLARISOY portfolio includes CLARISOY 100, 110, 120 and 150 for low potential of Hydrogen (pH) applications, and CLARISOY 170 and 180 for neutral applications. Peazazz is well-suited for use in low pH and neutral pH beverages, dairy alternative products, meal replacements, as well as a range of other healthy food and beverage product applications.
Receive News & Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.